US Patent Issued to Janssen Biotech on April 14 for "Serum albumin-binding fibronectin type III domains" (Pennsylvania Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,599,652, issued on April 14, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"Serum albumin-binding fibronectin type III domains" was invented by Michael Diem (Spring House, Pa.), Steven Jacobs (Spring House, Pa.), Karyn O'Neil (Spring House, Pa.) and Thomas Rutkoski (Spring House, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extendin...